Mechanisms of resistance to hormonal treatment in breast cancer

Clinical and Translational Oncology

Volumn 12, Issue 4, 2010, Pages 246-252

  Eroles, Pilar ^a   Bosch, Ana ^a   Bermejo, Begoña ^a   Lluch, Ana ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

AIB1; Breast cancer; CYPD2D6; Hormonal treatment; PAX2; Resistance; TK inhibitors

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; EVEROLIMUS; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LAPATINIB; LETROZOLE; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TIPIFARNIB; TRANSCRIPTION FACTOR PAX2; TRASTUZUMAB;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; GENOMICS; HUMAN; MOLECULAR INTERACTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 77952135293     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0500-1     Document Type: Review

References (64)

1. C.M. Perou T. Sørlie M.B. Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10.1038/35021093 10963602
2. T. Sørlie C.M. Perou R. Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
3. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
4. T. Saphner D.C. Tormey R. Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746 8874335
5. R. Dent M. Trudeau K.I. Pritchard, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR-06-3045 17671126 (Pubitemid 47219710)
6. G.T. Beatson 1896 On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 2 104 107 10.1016/S0140-6736(01)72307-0
7. M.H. Cohen S. Hirschfeld S. Flamm Honig, et al. 2001 Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene Oncologist 6 4 11 10.1634/theoncologist.6-1-4 11161223 (Pubitemid 32155810)
8. E.V. Jensen H.I. Jacobson 1962 Basic guides to the mechanism of estrogen action Recent Prog Horm Res 18 318 414
9. S. Green P. Walter V. Kumar, et al. 1986 Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A Nature 320 134 139 10.1038/320134a0 3754034
10. G.G. Kuiper E. Enmark M. Pelto-Huikko, et al. 1996 Cloning of a novel receptor expressed in rat prostate and ovary Proc Natl Acad Sci U S A 93 5925 5930 10.1073/pnas.93.12.5925 8650195 (Pubitemid 26190778)
11. J.A. Gustafsson 1999 Estrogen receptor beta-a new dimension in estrogen mechanism of action J Endocrinol 163 379 383 10.1677/joe.0.1630379 10588810
12. G.G. Kuiper B. Carlsson K. Grandien, et al. 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138 863 870 10.1210/en.138.3.863 9048584 (Pubitemid 27089735)
13. G.G. Kuiper J.G. Lemmen B. Carlsson, et al. 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 139 4252 4263 10.1210/en.139.10.4252 9751507
14. C.J. Gruber W. Tschugguel C. Schneeberger J.C. Huber 2002 Production and actions of estrogens N Engl J Med 346 340 352 10.1056/NEJMra000471 11821512 (Pubitemid 34438843)
15. P. Pace J. Taylor S. Suntharalingam, et al. 1997 Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha J Biol Chem 272 25832 25838 10.1074/jbc.272.41.25832 9325313 (Pubitemid 27438906)
16. A.E. Wakeling 2000 Similarities and distinctions in the mode of action of different classes of antioestrogens Endocr Relat Cancer 7 17 28 10.1677/erc.0.0070017 10808193
17. R. Schiff C.K. Osborne 2005 Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer Breast Cancer Res 7 205 211 10.1186/bcr1287 16168139 (Pubitemid 41387432)
18. R. Sanchez D. Nguyen W. Rocha, et al. 2002 Diversity in the mechanisms of gene regulation by estrogen receptors Bioessays 24 244 254 10.1002/bies.10066 11891761 (Pubitemid 34248690)
19. R. Schiff S.A. Massarweh J. Shou, et al. 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 331S 336S 10.1158/1078-0432.CCR-031212 14734488 (Pubitemid 38116639)
20. N. Atanaskova V.G. Keshamouni J.S. Krueger, et al. 2002 MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance Oncogene 21 4000 4008 10.1038/sj.onc.1205506 12037682 (Pubitemid 34679241)
21. Z. Chen I.S. Yuhanna Z. Galcheva-Gargova, et al. 1999 Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen J Clin Invest 103 401 406 10.1172/JCI5347 9927501
22. K. Hisamoto M. Ohmichi H. Kurachi, et al. 2001 Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells J Biol Chem 276 3459 3467 10.1074/jbc.M005036200 11044445
23. G. Flouriot H. Brand S. Denger, et al. 2000 Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1 EMBO J 19 4688 4700 10.1093/emboj/19.17.4688 10970861
24. Z. Wang X. Zhang P. Shen, et al. 2005 Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66 Biochem Biophys Res Commun 336 1023 1027 10.1016/j.bbrc.2005. 08.226 16165085 (Pubitemid 41383424)
25. Z. Wang X. Zhang P. Shen, et al. 2006 A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling Proc Natl Acad Sci U S A 103 9063 9068 10.1073/pnas.0603339103 16754886 (Pubitemid 43902533)
26. L. Shi B. Dong Z. Li, et al. 2009 Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer J Clin Oncol 27 3423 3429 10.1200/JCO.2008.17.2254 19487384
27. C.K. Osborne J. Shou S. Massarweh R. Schiff 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865s 870s 15701879 (Pubitemid 40111098)
28. E.A. Musgrove R.L. Sutherland 2009 Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631 643 10.1038/nrc2713 19701242
29. Z. Desta B.A. Ward N.V. Soukhova D.A. Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 10.1124/jpet.104.065607 15159443 (Pubitemid 39108928)
30. V. Stearns M.D. Johnson J.M. Rae, et al. 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 14652237
31. J.M. Hoskins L.A. Carey H.L. McLeod 2009 CYP2D6 and tamoxifen: DNA matters in breast cancer Nat Rev Cancer 9 576 586 10.1038/nrc2683 19629072
32. L.D. Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 229 2 43 10.1517/14622416.3.2.229 11972444 (Pubitemid 34223859)
33. Y. Jin Z. Desta V. Stearns B. Ward, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 15632378
34. H.S. Lim H. Ju Lee K. Seok Lee, et al. 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 3837 3845 10.1200/JCO.2007.11.4850 17761971 (Pubitemid 47477258)
35. V. Stearns M.D. Johnson J.M. Rae, et al. 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 14652237
36. S. Borges Z. Desta L. Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 10.1016/j.clpt.2006.03.013 16815318 (Pubitemid 43946844)
37. M.P. Goetz J.M. Rae V.J. Suman, et al. 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 10.1200/JCO.2005.03.3266 16361630
38. P. Wegman L. Vainikka O. Stål, et al. 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284 R290 10.1186/bcr993 15987423
39. S.A. Nowell J. Ahn J.M. Rae, et al. 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249 258 10.1007/s10549-004-7751-x 15952058 (Pubitemid 40903087)
40. P. Wegman S. Elingarami J. Carstensen, et al. 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7 10.1186/bcr1640 17244352 (Pubitemid 350215154)
41. J. Font de Mora M. Brown 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor Mol Cell Biol 20 5041 5047 10.1128/MCB.20.14.5041-5047.2000 10866661 (Pubitemid 30431558)
42. J. Shou S. Massarweh C.K. Osborne, et al. 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926 935 15199112
43. M. Dowsett C. Allred J. Knox, et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial J Clin Oncol 26 1059 1065 10.1200/JCO.2007.12.9437 18227529
44. T.A. Jackson J.K. Richer D.L. Bain, et al. 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT Mol Endocrinol 11 693 705 10.1210/me.11.6.693 9171233 (Pubitemid 27225297)
45. E.M. McInerney M.J. Tsai B.W. O'Malley B.S. Katzenellenbogen 1996 Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator Proc Natl Acad Sci U S A 93 10069 10073 10.1073/pnas.93.19.10069 8816752 (Pubitemid 26314575)
46. R.M. Lavinsky K. Jepsen T. Heinzel, et al. 1998 Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes Proc Natl Acad Sci U S A 95 2920 2925 10.1073/pnas.95.6.2920 9501191 (Pubitemid 28135830)
47. A.K. Shiau D. Barstad P.M. Loria, et al. 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 927 937 10.1016/S0092-8674(00)81717-1 9875847 (Pubitemid 29019045)
48. C.L. Smith Z. Nawaz B.W. O'Malley 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol Endocrinol 11 657 666 10.1210/me.11.6.657 9171229 (Pubitemid 27225293)
49. H.J. List R. Reiter B. Singh, et al. 2001 Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue Breast Cancer Res Treat 68 21 28 10.1023/A:1017910924390 11678305 (Pubitemid 32928267)
50. Q. Su S. Hu H. Gao, et al. 2008 Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells Oncology 75 159 168 10.1159/000159267 18827493
51. W. Zhao Q. Zhang X. Kang, et al. 2009 AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells Biochem Biophys Res Commun 380 699 704 10.1016/j.bbrc.2009.01.155 19285025
52. H. Wu Y. Chen J. Liang, et al. 2005 Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis Nature 438 981 987 10.1038/nature04225 16355216 (Pubitemid 43093965)
53. A. Hurtado K.A. Holmes T.R. Geistlinger, et al. 2008 Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen Nature 456 663 666 10.1038/nature07483 19005469
54. A.M. Redmond F.T. Bane A.T. Stafford, et al. 2009 Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence Clin Cancer Res 15 2098 2106 10.1158/1078-0432.CCR-08-1649 19276281
55. I. Girault F. Lerebours S. Amarir, et al. 2003 Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen Clin Cancer Res 9 1259 1266 12684393
56. M.J. Ellis A. Coop B. Singh, et al. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816 11559718
57. B. Kaufman J.R. Mackey M.R. Clemens, et al. 2009 Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 5529 5537 10.1200/JCO.2008.20.6847 19786670
58. Osborne K, Neven P, Dirix L et al (2007) Randomized Phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 106. Abstract 2067
59. Cristofanillin M, Valero V, Mangalik A et al (2008) A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Meeting Abstracts 1012
60. S. Johnston J. Pippen Jr X. Pivot M. Lichinitser, et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 5538 5546 10.1200/JCO.2009.23.3734 19786658
61. S.R. Johnston V.F. Semiglazov G.M. Manikhas, et al. 2008 A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy Breast Cancer Res Treat 110 327 335 10.1007/s10549-007- 9726-1 17851757 (Pubitemid 351793882)
62. J. Baselga V. Semiglazov P. van Dam, et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 10.1200/JCO.2008.18.8391 19380449
63. I.E. Smith G. Walsh A. Skene, et al. 2007 A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer J Clin Oncol 25 3816 22 10.1200/JCO.2006.09.6578 17679728 (Pubitemid 47477255)
64. J. Tabernero F. Rojo E. Calvo, et al. 2008 Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 1603 1610 10.1200/JCO.2007.14.5482 18332469